Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors

Дата публикации: 25-06-2026 00:00:00

This cohort study explores the long-term outcomes of patients with platinum-sensitive recurrent ovarian cancer who have exceptional response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Team finds way to reverse ovarian cancer’s chemo resistance	5	8	25-06-2026
2	Rethinking Treatment Intensification in Poorly Chemosensitive Ovarian Cancer	0	9.84	01-10-2026
3	Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer	0	7	25-06-2026
4	Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence	0	10	21-07-2026
5	Enzyme USP15 present a promising new target for ovarian cancer treatment	0	8.75	25-09-2026
6	Breast and Ovarian Cancer Among Individuals Undergoing BRCA1 and BRCA2 Testing	0	11.9	30-07-2026
7	Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions	0	5	23-06-2026
8	Serum and Tumor PD-L1 Expression and Aggressive Clinicopathologic Features in Papillary Thyroid Carcinoma	0	12.37	13-08-2026
9	GSK presents positive data for Mo-Rez in platinum-resistant ovarian cancer	0	19.5	23-10-2026
10	Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves EFS in PD-L1-positive, Resectable Gastric or GEJ Adenocarcinoma	5	7	30-06-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7. Источник: jamanetwork.com.